Biotheus Entered into a License and Collaboration Agreement with Hansoh Pharma for PM1080
Shots:
- Biotheus will receive $7.09M & is also eligible to receive ~$198.79M for future development, regulatory and commercialization milestones along with royalty based on net sales. The companies collaborated for Biotheus' PM1080, an EGFR/MET bispecific Ab in Greater China, incl. Mainland China, Hong Kong, Macao, and Taiwan
- Hansoh to get an exclusive right to develop, commercialize and manufacture PM1080 for the treatment of cancer, and will be responsible to assume all the costs in the territory
- In the preclinical data, PM1080 was safe and efficacious as monothx. or in combination with other anti-cancer agents, incl. EGFR TKIs. The therapy is currently undergoing GLP toxicity studies
Ref: PRNewswire | Image: Akeso
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
